Cue Biopharma Inc(CUE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -27 | Insider Own | 14.18% | Shs Outstand | 7.3M | Perf Week | 28.91% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | 70.24% | Insider Trans | -6.59% | Shs Float | 6.2M | Perf Month | 40.98% |
| Enterprise Value | 0.26B | PEG | - | EPS next Q | -2.24 | Inst Own | 22.6% | Short Float | 5.11% | Perf Quarter | 30.18% |
| Income | -0.16B | P/S | 7.15 | EPS this Y | -197.74% | Inst Trans | 19.08% | Short Ratio | 1.91 | Perf Half Y | 367.45% |
| Sales | 0.04B | P/B | 83.87 | EPS next 5Y | 7.19% | ROA | -459.6% | Short Interest | 0.32M | Perf YTD | 304.39% |
| Book/sh | 0.44 | P/C | 15.48 | EPS past 3/5Y | 42.63% 29.04% | ROE | -1603.48% | 52W High | -18.57% ($45.50) | Perf Year | 69.15% |
| Cash/sh | 2.39 | P/FCF | - | Sales past 3/5Y | 180.45% 54.16% | ROIC | -1729.46% | 52W Low | 645.32% ($4.97) | Perf 3Y | -48.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -63.33% | Gross Margin | 99.31% | Volatility(W/M) | 13.29% 12.12% | Perf 5Y | -90.43% |
| Dividend TTM | - | EV/Sales | 6.92 | Sales Y/Y TTM | 354.37% | Oper. Margin | -261.97% | ATR (14) | 3.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.25 | EPS Q/Q | -805.64% | Profit Margin | -435.83% | RSI (14) | 65.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.25 | Sales Q/Q | 166.66% | SMA20 | 27.03% ($29.17) | Beta | 2.56 | Target Price | $88 |
| Payout | - | Debt/Eq | 3.81 | Earnings | 2026/8/14 | SMA50 | 26.01% ($29.4) | Rel Volume | 2.29 | Prev Close | $37.84 |
| Employees | 29 | LT Debt/Eq | 3.11 | EPS/Sales Surpr. | -1328.4% 162.57% | SMA200 | 90.41% ($19.46) | Avg Volume(3M) | 0.17M | Price | $37.05 |
| IPO | 2018/1/2 | Option/Short | No/Yes | Trades | 2803 | Volume | 381,952 | Change | -2.09% |
Company
CUE is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Cue Biopharma is a clinical-stage biotech developing therapeutics for autoimmune diseases and oncology based on its proprietary platform for the precise modulation of immune cells. By selectively targeting specific T cells to elicit only the desired immune response, the company is building a next-generation immuno-oncology and autoimmune pipeline aimed at achieving fundamental treatment while reducing side effects.
Over the past 1 year, on the higher side
19% below its 1-year high.
CUE has weak earning power
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -197.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -48.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 22.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
AVSC 0.00%
AVTM 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $269M.
CUE $269M PER -
VRTX $129B PER 29.6
REGN $81B PER 19.4
ARGX $62B PER 37.7
FAQ
What kind of company is CUE?
CUE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CUE?
The market cap of CUE is approximately $269M, ranking 3,828 within its sector.
What is the 52-week high and low for CUE?
CUE has recorded a 52-week high of $45.50 and a low of $4.97.
